Market capitalization | €18.71b |
Enterprise Value | €31.71b |
P/E (TTM) P/E ratio | negative |
EV/FCF (TTM) EV/FCF | 10.09 |
EV/Sales (TTM) EV/Sales | 1.42 |
P/S ratio (TTM) P/S ratio | 0.84 |
P/B ratio (TTM) P/B ratio | 0.98 |
Dividend yield | 2.77% |
Last dividend (FY22) | €0.92 |
Set up alerts on Stock Price, Dividend Yield, Valuation (e.g. P/E or EV/Sales) or Strategy Scores and sit back and relax.
13 Analysts have issued a Fresenius forecast:
13 Analysts have issued a Fresenius forecast:
Jun '24 |
+/-
%
|
||
Revenue | 22,360 22,360 |
46%
46%
|
|
Gross Profit | 5,198 5,198 |
50%
50%
|
|
EBITDA | 2,895 2,895 |
51%
51%
|
EBIT (Operating Income) EBIT | 1,354 1,354 |
53%
53%
|
Net Profit | -1,115 -1,115 |
211%
211%
|
In millions EUR.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Fresenius SE & Co. KGaA is a healthcare group, which engages in the provision of products, and services for dialysis, hospitals, and outpatient medical care. It operates through the following segments: Fresenius Medical Care, Fresenius Kabi, Fresenius Helios, Fresenius Vamed, and Corporate and Other. The Fresenius Medical Care segment comprises dialysis products and healthcare services. The Fresenius Kabi segment specializes intravenous drugs, clinical nutrition, infusion therapy, medical devices, and transfusion technology. The Fresenius Helios focuses on the private hospital operations. The Fresenius Vamed segment manages projects and services for hospitals and other healthcare facilities. The Corporate and Other segment includes the holding activities. The company was founded by Eduard Fresenius in October 1912 and is headquartered in Bad Homburg, Germany.
Head office | Germany |
CEO | Michael Sen |
Employees | 193,865 |
Founded | 1912 |
Website | www.fresenius.de |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.